Liver cancer battle: which combo therapy wins?
NCT ID NCT07340502
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study compares two treatment combinations for advanced liver cancer that cannot be removed by surgery. One group gets TACE (a procedure that blocks blood flow to the tumor and delivers chemo directly) plus immunotherapy and a targeted drug. The other group gets HAIC (a continuous chemo infusion through a catheter) plus the same drugs. The goal is to see which approach works better and is safer. About 364 adults with newly diagnosed liver cancer will take part.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
PD-1 inhibitors and lenvatinib
What this could lead to
If this study shows HAIC is better than TACE for certain patients, it could lead to more effective, personalized treatment for advanced liver cancer.
What could go wrong
This is an observational study, not a randomized trial, so results may be less definitive. It is also early-stage, and the treatments have known side effects like fatigue, liver damage, and bleeding risks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HCC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••